Pharmacotherapy of major depression in late life: what is the role of new agents?

Pharmacotherapy of major depression in late life: what is the role of new agents?

Expert Opin Pharmacother. 2017 Mar 20;:

Authors: Patel K, Abdool PS, Rajji TK, Mulsant BH

Abstract
INTRODUCTION: Evidence on the pharmacotherapy of late-life major depressive disorder (LLD) is scant. Most of the recommendations in existing clinical guidelines are based on expert opinions, extrapolations from data obtained in younger patients, or theoretical considerations. AREAS COVERED This article summarizes the recommendations from existing clinical guidelines and recent reviews on the treatment of LLD. Next, it discusses the potential role of newer antidepressants -vilazodone, levomilnacipran, and vortioxetine- based on a systematic search of the literature published during the past five years. Then, it presents evidence pertaining to the use of ketamine, aripiprazole, brexpiprazole, quetiapine, and methylphenidate in the treatment of LLD. EXPERT OPINION Very few recent publications directly relevant to the pharmacotherapy of LLD were identified: there are no published data supporting the use of vilazodone, levomilnacipran, ketamine, or brexpiprazole in older patients. Recent placebo-controlled randomized controlled trials (RCTs) support the use of vortioxetine, quetiapine monotherapy, aripiprazole augmentation, or methylphenidate augmentation (with one RCT for each). Thus, overall, there have been few innovations in the pharmacotherapy of LLD over the past decade and the stepwise approach recommended in older guidelines remains relevant today. More studies addressing the relative efficacy, tolerability, and safety of psychotropic medications are needed.

PMID: 28317392 [PubMed - as supplied by publisher]

http://ift.tt/2nNubvx